<DOC>
	<DOCNO>NCT01099761</DOCNO>
	<brief_summary>The purpose study determine ACE-031 safe well-tolerated boy Duchenne Muscular Dystrophy ( DMD ) select optimal dos ACE-031 term safety pharmacodynamic ( PD ) activity design future study . [ Note : This study terminate base safety data ]</brief_summary>
	<brief_title>Study ACE-031 Subjects With Duchenne Muscular Dystrophy</brief_title>
	<detailed_description>ACE-031 , soluble form human activin receptor type IIB , administer every 2 4 week subcutaneous ( SC ) injection boys DMD . Dose level regimens multiple-dose study base data initial clinical study healthy subject dose 0.02 3 mg/kg SC evaluate . A total 24 subject enrol study ; 18 receive ACE-031 6 placebo . All subject treat period 12 weeks.The pharmacodynamic effect ACE-031 treatment assess battery motor function test include 6-Minute Walk Test , 10-Minute Walk/Run Test , 4-Stair Climb Test Gower Maneuver ( GW ) . Muscle strength assess hand-held myometry fix system test . Body composition ( i.e. , spine BMD , lean mass , fat mass ) assess whole body lumbar spine DXA scan . Pulmonary function assess force vital capacity ( FVC ) , maximal inspiratory pressure ( MIP ) maximal expiratory pressure ( MEP ) . ACE-031 safety evaluate observation incidence severity adverse event .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Diagnosis DMD confirm Ambulant Corticosteroid therapy least one year prior study day 1 stable dose schedule least 6 month prior study day 1 Evidence muscle weakness clinical assessment Any previous treatment another investigational product within 6 month prior study day 1 Any clinically significant cardiac , endocrine , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease relate DMD Inability perform whole body dual xray absorptiometry ( DXA ) scan</criteria>
	<gender>Male</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>